VCM
MACK

Virtue Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Virtue Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,451
Closed -$151K – 694
2017
Q4 		$151K Buy
+4,451
New +$41.5K 0.09% 186

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtue Capital Management's MACK Position: Q1 2018 in Review

Virtue Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2018, closing a stake of 4,451 shares — an estimated $151K sold.

Virtue Capital Management first reported a position in MACK in Q4 2017 and held it in 1 quarter. The position peaked at $151K in Q4 2017. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

  • Virtue Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Virtue Capital Management sold 4,451 Merrimack Pharmaceuticals, Inc. shares in Q1 2018, an estimated $151K.
  • Virtue Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Virtue Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $151K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Virtue Capital Management's 13F filing for Q1 2018, filed 15 May 2018.